Recent developments in the field of tumor-inhibiting metal complexes

Current Pharmaceutical Design

Volumn 9, Issue 25, 2003, Pages 2078-2089

  Galanski, M ^a   Arion, V B ^a   Jakupec, M A ^a   Keppler, B K ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; ANTINEOPLASTIC METAL COMPLEX; AP 5280; BISPHOSPHONIC ACID DERIVATIVE; BUDOTITANE; CARBOPLATIN; CISPLATIN; GALLIUM; INDAZOLIUM TETRACHLOROBIS(INDAZOLE)RUTHENATE; KP 46; KP 735; METAL COMPLEX; OXALIPLATIN; PLATINUM DERIVATIVE; PLATINUM ETHYLENEDIAMINE DICHLORIDE; PRODRUG; RAZOXANE; RUTHENIUM COMPLEX; SATRAPLATIN; THIOPLATIN; THIOSEMICARBAZONE DERIVATIVE; TRIS(8 QUINOLINOLATO)GALLIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; BLADDER CARCINOMA; BONE MARROW SUPPRESSION; COLON CARCINOMA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; EAR DISEASE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; KIDNEY DISEASE; LUNG CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR WEIGHT; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUROPATHY; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PH; PRIORITY JOURNAL; RAT; REVIEW; STOMACH CANCER; STRUCTURE ACTIVITY RELATION; TESTIS CANCER; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIGANDS; METALS, HEAVY;

EID: 0141811013     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033454180     Document Type: Review

References (116)

1. Sigel A, Sigel H. Metal Ions in Biological Systems 1-39: New York. Dekker;
2. Guo Z, Sadler PJ. Metals in Medicine. Angew Chem Int Ed Engl 1999; 38: 1512-31.
3. Lippert B. (E), Cisplatin: chemistry and biochemistry of a leading anticancer drug; Zürich Verlag Helvetica Chimica Acta, and Weinheim WILEY-VCH, 1999.
4. O'Dwyer PJ, Stevenson JP, Johnson SW. Clinical pharmacokinetics and administration of established platinum drugs. Drugs 2000; 59(Suppl. 4): 19-27.
5. Cvitkovic E, Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol 1999; 26: 647-62.
6. Allardyce CS, Dyson PJ. Ruthenium in medicine: Current clinical uses and future prospects. Platinum Metals Rev 2001; 45: 62-9.
7. Peyrone M. Über die Einwirkung des Ammoniaks auf Platinchlorid. Annalen der Chemie und Pharmacie 1844; LI: 1-29.
8. Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature 1969; 222: 385-6.
9. Rosenberg B, VanCamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965; 205: 698-9.
10. Rosenberg B. Platinum complexes for the treatment of cancer. Interdiscip Sci Rev 1978; 3: 134-47.
11. Jakupec MA, Galanski M, Keppler BK. Tumour-inhibiting platinum complexes - state of the art and future perspectives. Rev Physiol Biochem Pharmacol 2003; 146: 1-54.
12. Warburg O. The carcinoma problem. Z Angew Chem 1926; 39: 949-51.
13. Warburg O, Wind F, Negelein E. Metabolism of tumors in the body. Klin Wochschr 1926; 5: 829-32.
14. Thistlethwaite AJ, Leeper DB, Moylan DJ 3rd, Nerlinger RE. pH distribution in human tumors. Int J Radiat Oncol 1985; 11: 1647-52.
15. Stubbs M, Veech RL, Griffiths JR. Tumor metabolism: the lessons of magnetic resonance spectroscopy. Adv Enzyme Regul 1995; 35: 101-15.
16. Volk T, Jaehde E, Fortmeyer HP, Gluesenkamp KH, Rajewsky MF. pH in human tumor xenografts: effect of intravenous administration of glucose. Brit J Cancer 1993; 68: 492-500.
17. Raghunand N, Gillies RJ. pH and chemotherapy. Novartis Foundation Symposium 2001; 240 (Tumor Microenvironment): 199-211.
18. Altan N, Chen Y, Schindler M, Simon S. Defective acidification in human breast tumor cells and implications for chemotherapy. J Exp Med 1998; 187: 1583-98.
19. Amtmann E, Schilling G. Medicament containing platinum complex and its use. WO 0010543 2000.
20. Amtmann E, Zoller M, Wesch H, Schilling, G. Antitumoral activity of a sulphur-containing platinum complex with an acidic pH optimum. Cancer Chemother Pharmocol 2001; 47: 461-6.
21. Zimmermann W, Galanski M, Keppler BK, Giester G. Synthesis and structures of (SP-4-2)-diiodobis(2-hydroxyethylamine) platinum(II), (SP-4-2)-dichlorobis(2-hydroxyethylamine)platinum (II) and (OC-6-22)-bis(2-hydroxyethylamine)tetrachloroplatinum (IV) in the crystal. Inorg Chim Acta 1999; 292: 127-30.
22. 1H-HMQC NMR study. Eur J Inorg Chem 2001; 1145-9.
23. Galanski M, Baumgartner C, Arion V, Keppler BK. Bis(2-aminobutanol)dichloro-platinum(II) complexes and their mono and double ring-closed butanolato species. Novel prodrugs for platinum based antitumour chemotherapy? Eur J Inorg Chem 2003; in press.
24. Robillard MS, Galanski M, Zimmermann W, Keppler BK, Reedijk J. (Aminoethanol)dichloroplatinum(II) complexes: influence of the hydroxyethyl moiety on 5′-GMP and DNA binding, intramolecular stability, the partition coefficient and anticancer activity. J Inorg Biochem 2002; 88: 254-9.
25. Zenker A, Galanski M, Bereuter TL, Keppler BK, Lindner W. Time-dependent interactions of platinum(II) complexes with 5′-GMP under simulated physiological conditions studied by capillary electrophoresis. J Biol Inorg Chem 2000; 5: 498-504.
26. Küng A, Galanski M, Baumgartner C, Keppler BK. Reaction of (SP-4-2)-dichlorobis(2-hydroxyethylamine) platinum(II) with 5′-GMP under simulated physiological conditions, a CZE-ESI-MS study. Inorg Chim Acta 2002; 339: 9-13.
27. Evagorou EG, Duncan R, Buckley RG, Gianasi E. Preparation of polymer-platinum compounds as antitumor agents. WO 9847537 1998.
28. Duncan R, Gac-Breton S, Keane R, Musila R, Sat YN, Satchi R, et al. Polymer-drug conjugates, polymer-directed enzyme prodrug therapy (PDEPT) and (polymer-enzyme liposome therapy) PELT: basic principles for design and transfer from the laboratory to clinic. J Control Release 2001; 74: 135-46.
29. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-84.
30. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41: 189-207.
31. Paterson AHG. Bisphosphonates: biological response modifiers in breast cancer. Clin Breast Cancer 2002; 3: 206-16.
32. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A. et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20: 3219-24.
33. Galanski M, Keppler BK, Nuber B. First isolation of an enol of a carboxylic acid by complexation to an (ethane-1,2-diamine)platinum(II). Angew Chem Int Ed Eng 1995; 34: 1103-4.
34. Wingen F, Sterz H, Blum H, Moeller H, Pittermann W, Pool BL, et al. Synthesis, antitumor activity, distribution and toxicity of 4-[4-[bis(2-chloroethyl)amino]phenyl]-1-hydroxybutane-1,1-bisphosphonic acid (BAD), a new lost derivative with increased accumulation in rat osteosarcoma. J Cancer Res Clin Oncol 1986; 111: 209-19.
35. Galanski M, Slaby S, Keppler BK. The mode of action of antitumor platinum compounds linked to amino phosphonic acids with particular activity against bone malignancies and the influence of calcium ions onto the DNA binding behavior. In: Fiebig HH, Burger AM, Eds, Relevance of Tumor Models for Anticancer Drug Development, Vol. 54 of: Queisser W, Scheithauer W, Eds, Contributions to Oncology. Basel, Karger. 1999; 435-8.
36. Klenner T, Wingen F, Keppler BK, Krempien B, Schmähl, D. Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies? J Cancer Res Clin Oncol 1990; 116: 341-50.
37. Klenner T, Wingen F, Keppler B, Valenzuela-Paz P, Amelung F, Schmähl D. Therapeutic efficacy of two different cytostatic-linked phosphonates in combination with razoxane in the transplantable osteosarcoma of the rat. Clin Exp Metastasis 1990; 8: 345-59.
38. Klenner T, Valenzuela-Paz P, Amelung F, Muench H, Zahn H, Keppler BK, et al. Platinum phosphonato complexes with particular activity against bone malignancies. An evaluation of an experimental tumor model highly predictive for the clinical situation. In: Keppler BK Ed, Metal Complexes in Cancer Chemotherapy. Weinheim, VCH. 1993; 85-127.
39. Klenner T, Valenzuela-Paz P, Keppler BK, Scherf HR. Sensitivity of rodent osteosarcoma clones to platinum-containing phosphonic acid complexes in vitro. J Cancer Res Clin Oncol 1990; 116: 453-8.
40. Bloemink MJ, Dorenbos JP, Heetebrij RJ, Keppler BK, Reedijk J, Zahn H. New antitumor platinum compounds linked to amino phosphonic acids which lose the phosphonate and tertiary amine ligand upon binding to nucleic acids. Inorg Chem 1994; 33: 1127-32
41. Bloemink MJ, Diederen JJH, Dorenbos JP, Heetebrij RJ, Keppler BK, Reedijk J. Calcium ions do accelerate the DNA binding of new antitumor - active platinum aminophosphonate complexes. Eur J Inorg Chem 1999; 1655-7.
42. Slaby S, Galanski M, Metzger SW, Keppler BK. Design of platinum-complexes with high affinity for osteosarcoma and bone metastases - structure-activity relationship. In: Fiebig HH, Burger AM, Eds, Relevance of Tumor Models for Anticancer Drug Development, Vol. 54 of: Queisser W, Scheithauer W, Eds, Contributions to Oncology. Basel, Karger. 1999; 201-5
43. Ciandomenico CM, Abrams MJ, Murrer BA, Vollano JF, Rheinheimer MI, Wyer SB, et al. Carboxylation of kinetically inert platinum(IV) hydroxyl complexes. An entrée into orally active platinum(IV) antitumor agents. Inorg Chem 1995; 34: 1015-21.
44. Song R, Kim KM, Lee SS, Sohn YS. Electrophilic substitution of (diamine)tetrahydroxoplatinum(IV) with carboxylic anhydrides. Synthesis and characterization of (diamine)platinum(IV) complexes of mixed carboxylates. Inorg Chem 2000; 39: 3567-71.
45. Lee YA, Lee SS, Kim KM, Lee CO, Sohn YS. Synthesis and oral-antitumor activity of tetrakis(carboxylato)platinum (IV) complexes. J Med Chem 2000; 43: 1409-12.
46. Khokhar AR, Deng Y, Al-Baker S, Yoshida M, Siddik ZH. Synthesis and antitumor activity of ammine/amine platinum(II) and (IV) complexes. J Inorg Biochem 1993; 51: 677-87.
47. Neidle S, Snook CF, Murrer BA, Barnard CF. Bis(acetato) amminedichloro - (cyclohexylamine)platinum(IV), an orally active anticancer drug. Acta Crystallogr 1995; C51: 822-4.
48. McKeage MJ, Raynaud F, Ward J, Berry C, O'Dell D, Kelland LR et al.. Phase I pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997; 15: 2691-700.
49. Fokkema E, Groen HJM, Bauer J, Uges DRA, Weil C, Smith IE. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol 1999; 17: 3822-7.
50. Trudeau M, Stuart G, Hirte H, Drouin P, Plante M, Bessette P et al. A phase II trial of JM-216 in cervical cancer: an NCIC/CTG study. Gynecol Oncol 2002; 84: 327-31.
51. Galanski M, Keppler BK. Synthesis and characterization of new ethylenediamine platinum(IV) complexes containing lipophilic carboxylate ligands. Metal-Based Drugs 1995; 2: 57-63.
52. Galanski M, Keppler BK. Carboxylation of dihydroxoplatinum(IV) complexes via a new synthetic pathway. Inorg Chem 1996; 35: 1709-11.
53. Galanski M, Keppler BK. Carboxylation of dihydrooxoplatinum (IV) complexes with acyl chlorides. Crystal structure of the trans-R,R- and trans-S,S-isomer of (OC-6-33)-bis(1-adamantanecarboxylato)(cyclohexane-1,2-diamine) dichloroplatinum(IV). Inorg Chim Acta 1997; 265: 271-4.
54. Galanski M, Zimmermann W, Berger M, Baumgartner C, Giester G, Keppler BK. Carboxylation of 2-hydroxyethyl substituted tetrachloro(ethane-1,2-diamine)platinum(IV) complexes. A new synthetic approach to anticancer platinum compounds. Eur J Inorg Chem 2002; 417-21.
55. Guo Z, Sadler PJ, Medicinal inorganic chemistry. Adv Inorg. Chem. 1999; 49: 183-306.
56. Pieper T, Borsky K, Keppler BK. Non-platinum antitumor compounds. In: Clarke MJ, Sadler PJ Eds, Metallopharmaceuticals I, DNA Interactions, Vol. 1 of Top. Biol. Inorg. Chem. Berlin, Springer. 1999; 171-99.
57. Clarke MJ. Ruthenium metallopharmaceuticals. Coord Chem Rev 2003; 236: 209-33.
58. Espósito BP, Najjar R. Interactions of antitumoral platinum-group metallodrugs with albumin. Coord Chem Rev 2002; 232: 137-49.
59. Sava G, Bergamo A. Ruthenium-based compounds and tumor growth control. Int J Oncol 2000; 17: 353-65.
60. Sava G, Gagliardi R, Bergamo A, Allesio E, Mestroni G. Treatment of metastases of solid mouse tumors by NAMI-A. Comparison with cisplatin, cyclophosphamide and dacarbazine. Anticancer Res 1999; 19: 969-72.
61. Sava G, Cocchietto M. Blood levels of ruthenium following repeated treatments with the antimetastatic compound NAMI-A in healthy beagle dogs. In Vivo 2000; 14: 741-4.
62. Magnarin M, Bergamo A, Carotenuto ME, Zorzet S, Sava G. Increase of tumor-infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A. Anticancer Res 2000; 20: 2939-44.
63. Sava G, Alessio E, Bergamo A, Mestroni G. Sulfoxide ruthenium complexes: non-toxic tools for the selective treatment of solid tumor metastases. In: Clarke MJ, Sadler PJ Eds, Metallopharmaceuticals I, DNA Interactions, Vol. 1 of Top. Biol. Inorg. Chem. Berlin, Springer. 1999; 143-69.
64. Cocchietto M, Sava G. Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice. Pharmacol Toxicol 2000; 87: 193-7.
65. Zorzet S, Sorc A, Casarsa C, Cochietto M, Sava G. Pharmacological effects of the ruthenium complex NAMI-A given orally to CBA mice with MCa mammary carcinoma. Metal-Based Drugs 2001; 8: 1-7.
66. Sanna B, Debidda M, Pintus G, Tadolini B, Posadino AM, Bennardini F, et al. The antimetastatic agent imidazolium trans-imidazoledimethylsulfoxidetetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signalling pathway. Arch Biochem Biophys 2002; 403: 209-18.
67. Morris RE, Aird RE, Del S Murdoch P, Chen H, Cummings J, Hughes ND, et al. Inhibition of cancer cell growth by ruthenium(II) arene complexes. J Med Chem 2001; 44: 3616-21.
68. Aird RE, Cummings J, Muir M, Morris RE, Chen H, Sadler PJ, et al. In vitro and in vivo activity and cross resistance profiles of novel ruthenium(II) organometallic arene complexes in human ovarian cancer. Brit J Cancer 2002; 86: 1652-7.
69. Chen H, Parkinson JA, Parsons S, Coxall RA, Gould RO, Sadler PJ. Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts. J Am Chem Soc 2002; 124: 3064-82.
70. Wang F, Chen H, Parkinson JA, Murdoch P del S, Sadler PJ. Reactions of a ruthenium(II) arene antitumor complex with cysteine and methionine. Inorg Chem 2002; 41: 4509-23.
71. 2(Pta)] (pta = 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane) a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells. Chem Commun 2001; 1396-7.
72. Allardyce CS, Dyson PJ, Ellis DJ, Salter PA, Scopelliti R. Synthesis and characterisation of some water soluble ruthenium(II)-arene complexes and an investigation of their antibiotic and antiviral properties. J Organomet Chem 2003; 668: 35-42.
73. 2]. Acta Crystallogr 1984; C40: 929-32.
74. Velders AH, Kooijman H, Spek AL, Haasnoot JG, De Vos D, Reedijk J. Strong differences in the in vitro cytotoxicity of three isomeric dichlorobis(2-phenylazopyridine)ruthen-ium(II) complexes. Inorg Chem 2000; 39: 2966-7.
75. 2] (azpy = 2-(phenylazo)pyridine) and the products of its reactions with guanine derivatives. Inorg Chem 2000; 39: 3838-44.
76. Keppler BK, Henn M, Juhl UM, Berger MR, Niebl R, Wagner FE. New ruthenium complexes for the treatment of cancer. Prog Clin Biochem Med 1989; 10: 41-69.
77. Kreuser ED, Keppler BK, Berdel WE, Piest A, Thiel E. Synergistic antitumor interactions between newly synthesized ruthenium complexes and cytokines in human colon carcinoma cell lines. Semin Oncol 1992; 19: 73-81.
78. Keppler BK, Lipponer KG, Stenzel B, Kratz F. New tumor-inhibiting ruthenium complexes. In: Keppler BK Ed, Metal Complexes in Cancer Chemotherapy. Weinheim, VCH. 1993; 187-220.
79. Berger MR, Garzon FT, Keppler BK, Schmähl D. Efficacy of new ruthenium complexes against chemically induced autochthonous colorectal carcinoma in rats. Anticancer Res 1989; 9: 761-6.
80. Keppler BK, Dittrich C. Entwicklung neuer Medikamente gegen Krebs - einer Wiener Sicht. Perspektiven 1999; 4-5: 64.
81. Pieper T, Peti W, Sommer M, Keppler BK. Development of the tumor-inhibiting complex salt sodium trans-tetrachlorobis (indazole)ruthenate(III). In: Fiebig HH, Burger AM, Eds, Relevance of Tumor Models for Anticancer Drug Development, Vol. 54 of: Queisser W, Scheithauer W, Eds, Contributions to Oncology. Basel, Karger. 1999; 451-2.
82. Keppler BK, Eisenbrand G, Jakupec MA. New anticancer agents developed by the new drug development group (AWO). In: Fiebig HH, Burger AM, Eds, Relevance of Tumor Models for Anticancer Drug Development, Vol. 54 of: Queisser W, Scheithauer W, Eds, Contributions to Oncology. Basel, Karger. 1999; 361-7.
83. Peti W, Pieper T, Sommer M, Keppler BK. Synthesis of tumour-inhibiting complex salts containing the anion (OC-6-11)-tetrachlorobis(indazole)ruthenate(III) and crystal structure of the tetraphenylphosphonium salt. Eur J Inorg Chem 1999; 1551-5.
84. Eastman A. The mechanism of action of cisplatin: from adducts to apoptosis. In Cisplatin: chemistry and biochemistry of a leading anticancer drug, ed. Lippert B, Wiley-VCH, Weinheim, 1999, pp. 111-134.
85. Howe-Grant M, Lippard SL. Aqueous platinum(II) chemistry; binding to biological molecules. In: Sigel H Ed, Metal Ions Biol Syst, 1980; 11: 63-125.
86. Pieper T, Peti W, Keppler BK. Solvolysis of the tumor-inhibiting Ru(III)-complex trans- tetrachlorobis(indazole) ruthenate(III). Metal-Based Drugs 2000; 7: 225-32.
87. 2] investigated by means of HPCE and HPLC-MS. J Biol Inorg Chem 2001; 6: 292-9.
88. Lipponer KG, Vogel E, Keppler BK. Synthesis, characterisation and solution chemistry of trans-indazoliumtetrachlorobis (indazole)ruthenate(III), a new anticancer ruthenium complex. IR, UV, NMR. HPLC investigations and antitumor activity. Crystal structures of trans-1-methyl-indazoliumtetrachlorobis(1-methylin-dazole) ruthenate(III) and its hydrolysis product trans-monoaqua-trichlorobis(1-methylindazole)ruthenate(III). Metal-Based Drugs 1996; 3: 243-60.
89. 2] (ind = indazole). Z Anorg Allg Chem 2001; 627: 261-5.
90. Kukushkin, Yu N. In Chemistry of Coordination Compounds, Moscow, Vysshaya shkola, 1985, 406.
91. Kratz F, Mulinacci N, Messori L, Bestini I, Keppler BK. Kinetic, spectroscopic and LPLC studies of the interactions of antitumor ruthenium(III) complexes with serum proteins. In: Anastassopoulou J, Collery P, Etienne JC, Theophanides T Eds, Metal Ions in Biology and Medicine, Vol 2. Paris, John Libbey Eurotext, 1992; 69-74.
92. Kratz F. Interactions of antitumor metal complexes with serum proteins. Perspectives for anticancer drug development. In: Keppler BK Ed, Metal Complexes in Cancer Chemotherapy. Weinheim, VCH 1993; 391-429.
93. Kratz F, Keppler BK, Messori L, Smith C, Baker EN. Protein-binding properties of two antitumour Ru(III) complexes to human apotransferrin and apolactoferrin. Metal-Based Drugs 1994; 1: 169-73.
94. Smith CA, Sutherland-Smith AJ, Keppler BK, Kratz F, Baker EN. Binding of ruthenium(III) antitumor drugs to human lactoferrin probed by high resolution X-ray crystallographic structure analyses. J Biol Inorg Chem 1996; 1: 424-31.
95. Kratz F, Hartmann M, Keppler BK, Messori L. The binding properties of two antitumor ruthenium(III) complexes to apotransferrin. J Biol Chem 1994; 269: 2581-8.
96. Kratz F, Keppler BK, Hartmann M, Messori L, Berger MR. Comparison of the antiproliferative activity of two antitumour ruthenium(III) complexes with their apotransferrin and transferrin-bound forms in human colon cancer cell line. Metal-Based Drugs 1996; 3: 15-24.
97. Küng A, Pieper T, Keppler BK. Investigations into the interaction between tumor-inhibiting Ru(III)-complexes and nucleotides by means of capillary electrophoresis. J Chromatogr 2001; B759: 81-9.
98. Malina J, Novakova O, Keppler BK, Alessio E, Brabec V. Biophysical analysis of natural, double-helical DNA modified by anticancer heterocyclic complexes of ruthenium(III) in cell-free media. J Biol Inorg Chem 2001; 6: 435-45.
99. Arion VB, Eichinger A, Reisner E, Giester G, Keppler BK. A novel derivative of anti-tumour trans-tetrachlorobis (indazole)ruthenate (III): synthesis, structure, magnetism and spectroscopic properties; submitted.
100. Collery P, Keppler BK, Madoulet C, Desoize B. Gallium in cancer treatment. Crit Rev Oncol/Hematol 2002; 42: 283-96.
101. Clarke MJ, Zhu F, Frasca DR. Non-platinum chemotherapeutic metallopharmaceuticals. Chem Rev 1999; 99: 2511-33.
102. Arion VB, Jakupec MA, Galanski M, Unfried P, Keppler BK. Synthesis, structure, spectroscopic and in vitro antitumor studies of a novel gallium(III) complex with 2-acetylpyridine 4N-dimethylthiosemicarbazone. J Inorg Biochem 2002; 91: 298-305.
103. Bernstein LR, Tanner T, Godfrey C, Noll B. Chemistry and pharmacokinetics of gallium maltolate, a compound with high oral gallium bioavailability. Metal-Based Drugs 2000; 7: 33-47.
104. Collery P, Domingo JL, Keppler BK. Preclinical toxicology and tissue gallium distribution of a novel antitumour gallium compound: tris(8-quinolinolato)gallium(III). Anticancer Res 1996; 16: 687-92.
105. Gey D, Schilling T, Keppler BK, Thiel M, Schmidt-Gayk H, Raue F, et al. KP46, a new organometallic gallium complex is a strong inhibitor of tumor growth and hypercalcemia of malignancy; a study in rats. Exp Clin Endocrinol Diabetes 1997; 105 (Suppl 1): 6
106. Winter B, Schilling T, Gey DC, Keppler BK, Ziegler R. KP46, a new chemotherapeutic drug exerts its antitumor effect by induction of apoptosis. Exp Clin Endocrinol Diabetes 1998; 106 (Suppl 1): 83-4.
107. Collery P, Lechenault F, Cazabat A, Juvin E, Khassanova L, Evangelou A, et al. Inhibitory effects of gallium chloride and tris-(8-quinolinolato)gallium(III) on A549 human malignant cell line. Anticancer Res 2000; 20: 955-8.
108. Thiel M, Schilling T, Gey DC, Ziegler R, Collery P, Keppler BK. Tris(8-quinolinolato)-gallium(III), a novel orally applied antitumor gallium compound. In: Fiebig HH, Burger AM, Eds, Relevance of Tumor Models for Anticancer Drug Development, Vol. 54 of: Queisser W, Scheithauer W, Eds, Contributions to Oncology. Basel, Karger. 1999; 439-43.
109. Desoize B, Keppler BK, Akéli MG, Etienne JC, Collery P. Tris(8-quinolinolato)Ga(III) is active against unicellular and multicellular resistance. In: Centeno JA, Collery P, Vernet G, Finkelman RB, Gibb H, Etienne JC Eds, Metal Ions in Biology and Medicine; Vol 6. Paris, Libbey Eurotext, 2000; 573-6.
110. Jakupec MA, Collery P, Keppler BK. Interactions of tris(8-quinolinolato)gallium(III) (KP46) with platinum drugs in ovarian and colon carcinoma cells. Proc Am Ass Cancer Res 2001; 42: 425.
111. Sidwell RW, Huffman, JH, Scafer TW, Shipman C. Influnce of vehicle on topical efficacy of 2-acetylpyridine thiosemicarbazone and related derivatives on in vivo type 2 herpes simplex virus infections. Chemotherapy 1990; 36: 58-69.
112. Shipman C, Jr, Smith SH, Drach JC, Klayman DL. Thiosemicarbazones of 2-acetylpyridine, 2-acetylquinoline, 1-acetylisoquinoline, and related compounds as inhibitors of herpes simplex virus in vitro and in a cutaneous herpes guinea pig model. Antiviral Res 1986; 6: 197-222.
113. Kratz F, Nuber B, Weiß J, Keppler B.K. Interactions of tris(8-quinolinolato)gallium(III) (KP46) with platinum drugs in ovarian and colon carcinoma cells. Synth React Inorg Met-Org Chem 1991; 21: 1601-15.
114. Frenkel GD, Caffrey PB. A prevention strategy for circumventing drug resistance in cancer chemotherapy. Curr Pharm Des 2001; 7(16): 1595-614.
115. Jones G. B. and Fouad F. S. Designed enediyne antitumor agents. Curr Pharm Des 2002; 8(27): 2415-40.
116. Shih C, Teicher BA. Cryptophycins: a novel class of potent antimitotic antitumor depsipeptiDes Curr Pharm Des 2001; 7(13): 1259-76.